tert-butyl hydrogen diethylphosphoramidite

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: tert-butyl hydrogen diethylphosphoramidite
• 英文别名: N,N-diethyl-[(2-methylpropan-2-yl)oxy]phosphonamidous acid
• 化学式: C₈H₂₀NO₂P
• 分子量: 193.226
• InChiKey: AJEAVUSUNDZGCJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  二-(二乙基氨基)-叔丁氧基膦 在 盐酸 作用下， 以 二氯甲烷 为溶剂， 生成 tetraethyldiamidophosphite 、 tert-butyl hydrogen diethylphosphoramidite
  参考文献：
  名称：

  Gazizov, T. Kh.; Sal'keeva, L. K.; Gafurov, E. K., Journal of general chemistry of the USSR, 1988, vol. 58, # 4, p. 838 - 839

  摘要：

  DOI：

文献信息

• [EN] NOVEL NITROPHENYL MUSTARD AND NITROPHENYLAZIRIDINE ALCOHOLS AND THEIR CORRESPONDING PHOSPHATES AND THEIR USE AS TARGETED CYTOTOXIC AGENTS<br/>[FR] NOUVELLE MOUTARDE NITROPHENYLE ET NOUVEAUX ALCOOLS NITROPHENYLAZIRIDINE, PHOSPHATES CORRESPONDANTS ET UTILISATION DE CES DERNIERS EN TANT QU'AGENTS CYTOTOXIQUES CIBLES
  申请人：AUCKLAND UNISERVICES LTD

  公开号：WO2005042471A1

  公开（公告）日：2005-05-12

  The present invention relates to novel nitrophenyl mustard and nitrophenylaziridine alcohols, to their corresponding phosphates, to their use as targeted cytotoxic agents; as bioreductive drugs in hypoxic tumours, and to their use in cell ablation, including gene-directed enzyme-prodrug therapy (GDEPT) and antibody-directed enzyme­prodrug therapy (ADEPT), in conjunction with nitroreductase enzymes.

  本发明涉及新型硝基苯基芥和硝基苯基环丙胺醇，它们的相应磷酸盐，以及它们作为靶向细胞毒性药剂的用途；作为缺氧肿瘤中的生物还原药物，并且它们在细胞消融中的应用，包括基因导向酶前药治疗（GDEPT）和抗体导向酶前药治疗（ADEPT），与硝基还原酶酶一起。
• [EN] BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS<br/>[FR] ANALOGUES DE SPHINGOSINE 1-PHOSPHATE D'ARYLE BICYCLIQUE
  申请人：BIOGEN IDEC INC

  公开号：WO2010051030A1

  公开（公告）日：2010-05-06

  Compounds that have agonist activity at one or more of the SlP receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S lP receptors.

  提供了一种或多种SlP受体的激动剂活性的化合物。这些化合物是鞘氨醇类似物，磷酸化后可以在SlP受体上表现为激动剂。
• [EN] THERAPEUTIC QUINAZOLINE DERIVATIVES<br/>[FR] DERIVES THERAPEUTIQUES DE QUINAZOLINE
  申请人：ASTRAZENECA AB

  公开号：WO2004058782A1

  公开（公告）日：2004-07-15

  Quinazoline derivatives of formula (I): wherein A is 6-membered heteroaryl containing a nitrogen atom and optionally containing one or two further nitrogen atoms; compositions containing them, processes for their preparation and their use in therapy.

  式(I)的喹唑啉衍生物：其中A是含有一个氮原子的6元杂芳基，并且可选择性地含有一个或两个进一步的氮原子；包含它们的组合物，其制备方法以及在治疗中的用途。
• [EN] 7-NITROINDOLINE DERIVATIVES AND THEIR USES<br/>[FR] DERIVES DE 7-NITROINDOLINE ET LEURS UTILISATIONS
  申请人：MEDICAL RES COUNCIL

  公开号：WO2004085394A1

  公开（公告）日：2004-10-07

  7-nitroindoline compounds are disclosed that comprise a triplet sensitising group such as substituted or unsubstituted benzophenone group and can be used to cage effector species. In particular, the inclusion of a triplet sensitising group linked to the 4 or 5 position of a 7-nitroindoline derivative provides compounds which can be photolysed to release the effector species with unexpectedly enhanced photolysis efficiency. The triplet sensitising group may be linked directly to the 7-nitroindoline or via a spacer group. In some examples, the triplet sensitising group and/or the spacer group can be selected to enhance other properties of the caged compound such as its solubility, spectroscopic properties or stability (e.g. stability of the linkage between the nitroindoline moiety and the triplet sensitiser). This can help to improve the performance of the caged compound, especially in aqueous environments containing dissolved oxygen.

  本文介绍了一种包含三重敏化基团的7-硝基吲哚化合物，例如取代或未取代的苯基酮基团，并可用于封闭效应物种。特别是，将三重敏化基团连接到7-硝基吲哚衍生物的4或5位上，可提供可光解化合物，其光解效率意外增强，从而释放效应物种。三重敏化基团可以直接连接到7-硝基吲哚或通过间隔基团连接。在某些示例中，可以选择三重敏化基团和/或间隔基团以增强封闭化合物的其他性质，例如其溶解性，光谱性质或稳定性（例如硝基吲哚基团和三重敏化剂之间的连接的稳定性）。这有助于提高封闭化合物的性能，特别是在含有溶解氧的水环境中。
• Bicyclic aryl sphingosine 1-phosphate analogs
  申请人：Caldwell Richard D.

  公开号：US20100160258A1

  公开（公告）日：2010-06-24

  Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.

  提供具有激动S1P受体活性的化合物。这些化合物是鞘氨醇类似物，在磷酸化后，可以在S1P受体上表现为激动剂。